Jean‐Yves Cahn

Medicine · Health Sciences

56h-index15.1kcitations300works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(115), Hematopoietic Stem Cell Transplantation(100), Acute Lymphoblastic Leukemia research(66), Chronic Myeloid Leukemia Treatments(41), Chronic Lymphocytic Leukemia Research(29)

Publications299 total

Reinforcement Learning for Gliding Projectile Guidance and Control
arXiv (Cornell University)·2025Open Access
Rapid response system for critically ill patients with haematological malignancies: <scp>A</scp> pre‐ and post‐intervention study
European Journal Of Haematology·2024· 2 cited
Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
Blood·2023· 5 cited
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
Blood Advances·2023· 22 citedOpen Access
Data from Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
2023Open Access
Supplementary Data from Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
2023Open Access
Data from Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
2023Open Access
Supplementary Data from Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
2023Open Access
Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy
Transplantation and Cellular Therapy·2022· 18 citedOpen Access
Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis
Transplantation and Cellular Therapy·2022· 30 citedOpen Access
The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis
Haematologica·2022· 24 citedOpen Access
Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
Bone Marrow Transplantation·2022Open Access
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors
JAMA Oncology·2022· 73 citedOpen Access
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
Blood Advances·2021· 74 citedOpen Access
Conventional chemotherapy for acute myeloid leukemia in older adults: Impact on nutritional, cognitive, and functional status
European Journal Of Haematology·2021· 5 cited
Risk factors of BK viral hemorrhagic cystitis in allogenic hematopoietic stem cell transplantation
Transplant Infectious Disease·2021· 28 cited
Impact of Chronic Graft-Versus-Host Disease on First Late Effect Among Adult Survivors of Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis
Transplantation and Cellular Therapy·2021
First Late Effect in Pediatric Survivors with Chronic Graft-Versus-Host Disease Following Hematopoietic Cell Transplantation for Hematologic Malignancy
Transplantation and Cellular Therapy·2021
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Leukemia·2020· 10 citedOpen Access
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.
Digital Commons@Becker (Washington University School of Medicine)·2020Open Access
page 1 of 15Next →

Frequent Co-authors

Nöel Milpied(11), Robert Peter Gale(9), Hervé Dombret(9), Norbert Ifrah(9), Xavier Thomas(9), Didier Blaise(7), Pierre Bordigoni(7), Gèrard Socié(6), Daniel J. Weisdorf(6), Michel Attal(6), Norbert Vey(6), Rammurti T. Kamble(6), Bipin N. Savani(6), Baldeep Wirk(6), Pierre Biron(5), Christopher Bredeson(5), Harry C. Schouten(5), Mary M. Horowitz(5), Christian Récher(5), Mathieu Kuentz(5)